

April 18, 2018



## Rigel Announces Proposed Public Offering Of Common Stock

SOUTH SAN FRANCISCO, Calif., April 18, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it intends to offer and sell up to 15,000,000 shares of its common stock in an underwritten public offering. Rigel expects to grant the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock sold in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the offering are to be sold by Rigel, with the proceeds to be used for activities in connection with the commercial launch of TAVALISSE in the United States, research and development and general corporate purposes.

Jefferies LLC, Piper Jaffray & Co. and BMO Capital Markets Corp. are acting as the joint book-running managers of the offering. H.C. Wainwright & Co., LLC is acting as lead manager for the offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at [www.sec.gov](http://www.sec.gov). When available, copies of the preliminary prospectus supplement may also be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at [Prospectus\\_Department@Jefferies.com](mailto:Prospectus_Department@Jefferies.com), from Piper Jaffray & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at [prospectus@pjc.com](mailto:prospectus@pjc.com), or from BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, or by telephone at (800) 414-3627 or by email at [bmopropectus@bmo.com](mailto:bmopropectus@bmo.com).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

### **About Rigel Pharmaceuticals, Inc.**

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering,

developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor. Rigel's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy. In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.

***Forward-Looking Information is Subject to Risk and Uncertainty***

*Certain of the statements made in this press release are forward looking, such as those, among others, relating to Rigel's expectations regarding the completion of the proposed public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not Rigel will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Rigel will be able to complete the proposed public offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to the proposed offering, Rigel and its business can be found under the heading "Risk Factors" in Rigel's Annual Report on Form 10-K for the year ended December 31, 2017 and other filings with the SEC, and in the preliminary prospectus supplement related to the proposed offering to be filed with the SEC on or about the date hereof. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.*

Contact: Raul Rodriguez  
Phone: 650.624.1302  
Email: [invrel@rigel.com](mailto:invrel@rigel.com)

Media Contact: Jessica Daitch  
Phone: 917.816.6712  
Email: [jessica.daitich@inventivhealth.com](mailto:jessica.daitich@inventivhealth.com)



Logo - [https://mma.prnewswire.com/media/138092/rigel\\_pharmaceuticals\\_inc\\_logo.jpg](https://mma.prnewswire.com/media/138092/rigel_pharmaceuticals_inc_logo.jpg)

View original content with multimedia: <http://www.prnewswire.com/news-releases/rigel-announces-proposed-public-offering-of-common-stock-300632542.html>

SOURCE Rigel Pharmaceuticals, Inc.